CA-CLICKHOUSE
30.7.2024 16:01:35 CEST | Business Wire | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytical database, is thrilled to announce the acquisition of PeerDB, a leading provider of change data capture (CDC) solutions for Postgres databases. This strategic acquisition underscores ClickHouse’s commitment to delivering unparalleled real-time analytics and data integration capabilities to its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730221289/en/
ClickHouse acquires PeerDB to boost real-time analytics with Postgres CDC integration (Graphic: Business Wire)
PeerDB’s technology significantly reduces the time it takes to connect data in transactional databases like Postgres with analytical databases like ClickHouse, boosting developer productivity and time-to-value when building real-time data driven applications. With PeerDB CDC technology integrated into ClickHouse Cloud, users will benefit from seamless, real-time data replication from Postgres databases to ClickHouse.
“We are excited to welcome PeerDB into ClickHouse,” said Aaron Katz, CEO of ClickHouse, Inc. “This acquisition aligns with our mission to empower our customers with the most advanced and efficient data analytics solutions. By integrating PeerDB’s CDC technology, we are empowering Postgres developers to move even faster when building real-time data driven applications. Now, all they have to do is configure a mirror between their existing Postgres databases and ClickHouse, and the data is available for lightning-fast analytical queries.”
Sai Krishna Srirampur, CEO of PeerDB, expressed his enthusiasm for what the future holds, stating, “We are thrilled to join forces with ClickHouse. This acquisition is a natural evolution for us at PeerDB, as we already share many joint enthusiastic users with ClickHouse. Postgres is becoming the de facto operational database, while ClickHouse is the fastest analytical database on the planet. Both originate from the same open-source ethos. This acquisition bridges the gap between Postgres and ClickHouse, enabling businesses to seamlessly move their operational data for real-time analytics.”
Javier Erro Garcia, Cloud Architecture Manager at Vueling Airlines, shared excitement about the upcoming integration: “As a user of both ClickHouse Cloud and PeerDB, I am thrilled about this acquisition. We already reduced our Postgres to ClickHouse snapshot times from 10+ hours down to 15 minutes with PeerDB. Combining ClickHouse’s powerful analytics natively with PeerDB’s real-time data capture capabilities will greatly simplify our data processing workflows. This integration will enable us to build analytical applications faster, giving us a competitive edge in the market.”
The combined expertise of ClickHouse and PeerDB will pave the way for the development of new features and capabilities aimed at meeting the evolving needs of data-driven enterprises. Customers can look forward to deeper integration between PeerDB Cloud and ClickHouse Cloud and support for additional CDC data sources. The ClickHouse technical blog post introducing the acquisition provides more detail.
About ClickHouse
ClickHouse is a fast, open-source, columnar OLAP database management system. It allows users to generate analytics using SQL queries in real-time. Designed to analyze large volumes of data, ClickHouse is used by industry leaders around the globe for its unmatched performance, scalability, and reliability.
About PeerDB
PeerDB is a leading provider of change data capture (CDC) solutions for Postgres databases. Their technology enables real-time data replication and synchronization, helping businesses keep their data up-to-date and accessible for analytics and decision-making processes.
PeerDB was founded by Kaushik Iska and Sai Srirampur in mid 2023 and has since grown to become a leading Postgres data replication company in the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730221289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom